Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1

Interventions

pembrolizumab 44Carboplatin 40Cisplatin 36Paclitaxel 29Nivolumab 24Pemetrexed 24Gemcitabine 23Dexamethasone 21Rituximab 18Ipilimumab 16Cyclophosphamide 15Capecitabine 14Fluorouracil 14Docetaxel 13atezolizumab 13Lenalidomide 12Trastuzumab 12trastuzumab deruxtecan 12Cytarabine 11daratumumab 11durvalumab 11130-nm albumin-bound paclitaxel 10Bevacizumab 10Bortezomib 10Prednisone 10olaparib 10Doxorubicin 9Crizotinib 8Oxaliplatin 8venetoclax 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × Surgical Procedures, Operative × Clear all
NCT03924895 2025-08-28

KEYNOTE-905

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
595 enrolled 1 FDA
Genitourinary

Urinary Bladder Neoplasms

NCT03800134 2025-06-11

AEGEAN

AstraZeneca

Phase 3 Active not recruiting
825 enrolled 1 FDA
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT03493854 2024-06-26

FeDeriCa

Hoffmann-La Roche

Phase 3 Completed
500 enrolled 28 charts 1 FDA
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡